文献速递治疗药物监测与药物基因组学特殊人群用药

实体器官移植个体化医疗与无创诊断进展

Advances in personalized medicine and noninvasive diagnostics in solid organ transplantation.
PubMed 文献 · Pharmacotherapy · 2021-02-04

本文为观点性综述,总结实体器官移植个体化药物治疗的现有与新兴工具,包括药物基因组学、无创生物标志物(cfDNA、基因表达谱)及人工智能平台(如iBox),旨在优化免疫抑制治疗与移植排斥监测。

要点

  • 药物基因组学检测可为高危患者提供剂量优化依据,减少毒性并降低排斥风险。
  • cfDNA与基因表达谱作为「液体活检」有望无创监测移植物损伤并指导免疫抑制调整。
  • 人工智能平台如iBox可整合大数据,辅助个体化免疫抑制治疗决策。

核心结论

  • 药物基因组学、无创生物标志物和人工智能技术的进展有望推动实体器官移植个体化治疗与移植物功能监测的变革。

研究设计与样本

  • 本文为观点性综述,总结实体器官移植个体化医疗与无创诊断的现有及新兴工具、支持文献与未来方向。

主要发现

  • 药物基因组学检测可提供额外数据,帮助临床医生在高危患者中减少毒性并最大化治疗剂量。
  • 无创监测策略(如cfDNA和基因表达谱)可能提供更安全便捷的方法检测移植物损伤。
  • cfDNA和基因表达谱有潜力作为「液体活检」,提供分子数据以个体化免疫抑制和排斥治疗。
  • 大数据和新型AI平台(如iBox)有望提供更个体化的免疫抑制治疗以最小化未来不良结局。

临床怎么用

  • 临床可考虑用药物基因组学检测辅助高危移植患者的免疫抑制剂剂量决策。
  • 无创生物标志物(cfDNA、基因表达谱)可作为潜在工具用于监测移植物功能并指导免疫抑制调整。
  • AI平台如iBox可整合大数据辅助个体化免疫抑制治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Personalized medicine has been a mainstay and in practice in transplant pharmacotherapy since the advent of the field. Decisions pertaining to the diagnosis, selection, and monitoring of transplant pharmacotherapy are aimed toward the individual, the allograft, and the overall immunologic needs of the patient. Recent advances in pharmacogenomics, noninvasive biomarkers, and artificial intelligence (AI) technologies have the promise of transforming the way we individualize treatment and monitor allograft function. Pharmacogenomic testing can provide clinicians with additional data that can minimize toxicity and maximize therapeutic dosing in high-risk patients, leading to more informed decisions that may decrease the risk of rejection and adverse outcomes related to immunosuppressive therapies. Development of noninvasive strategies to monitor allograft function may offer safer and more convenient methods to detect allograft injury. Cell free DNA and gene expression profiling offer the potential to serve as "liquid biopsies" minimizing the risk to patients and providing clinicians with useful molecular data that may help individualize immunosuppression and rejection treatment. Use of big data in transplant and novel AI platforms, such as the iBox, hold tremendous promise in providing clinicians a "glimpse into the future" thereby allowing for a more individualized approach to immunosuppressive therapy that may minimize future adverse outcomes. Advances in diagnostics, laboratory science, and AI have made the application of personalized medicine even more tailored for solid organ transplant recipients. In this perspective, we summarize the current and emerging tools available, literature supporting use, and the horizon for future personalization of transplantation.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Maldonado AQ, West-Thielke P, Joyal K, et al. Advances in personalized medicine and noninvasive diagnostics in solid organ transplantation. Pharmacotherapy. 2021. PMID: 33156560. doi:10.1002/phar.2484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。